H. Kunz and G. Zech
FULL PAPER
3J=4.9 Hz, H-6b); 3.60, 3.57R (t, 1H, 3J=6.6 Hz, CH2OH); 1.39, 1.30,
1.25, 1.15, 1.13, 1.11, 1.07 (m, 52H, 3îPiv tBu, tBu, 2îMe, 5îCH2) ppm;
MS (ES+): m/z: 909.7 [M+Na]+.
(2R)-N-Formyl-N-[6-O-(8-hydroxy-2,2-dimethyloctanoyl)-2,3,4-tri-O-piv-
aloyl-b-d-galactopyranosyl]-valine-tert-butyl amide (13 f): Cleavage A:
Yield: 2.1 mg (68%), colorless oil; Rf =0.43 (petroleum ether/ethyl ace-
tate (4:1)); LC-MS: tR =5.72 (minor); 6.22 (major) min; d.r. 9:91
(ELSD), purity: 99% (ELSD). Cleavage B: Yield: 6 mg (96%), colorless
oil; LC-MS: tR =5.60; 6.13 min; d.r. 7:93 (ELSD), purity: 95% (ELSD).
Separation of diastereomers by semi-preparative HPLC (Luna C-18,
MeCN (80%!100%), 30 min): S isomer: Yield: <1 mg, tR =18.9 min;
1H NMR (CDCl3, 400 MHz): d=8.54, 8.48R (s, 1H, CHO); 6.16 (s, 1H,
N-Formyl-N-[6-O-(8-hydroxy-2,2-dimethyloctanoyl)-2,3,4-tri-O-pivaloyl-
b-d-galacto-pyranosyl]-phenylglycine-tert-butyl amide (13c): Cleavage A:
Yield: 3.8 mg (58%), colorless oil; Rf =0.27 (cyclohexane/ethyl acetate
(4:1)); LC-MS: tR =5.17 (minor); 6.55 (major) min; d.r. 4:96 (ELSD),
purity 98% (ELSD); MS (ES+): m/z: 841.6 [M+Na]+. On a larger scale
(12c: 540 mg, approximately 0.216 mmol) cleavage allows the separation
of the diastereomers by preparative HPLC (Luna C-18, MeCN (80%!
100%), 60 min, l=215 nm): S isomer: tR =54.0 min; yield: 13 mg (7%);
3
3
NH); 6.01, 4.99R (d, 1H, J=9.0 Hz, H-1); 5.59 (t, 1H, J=10.0 Hz, H-2);
3
5.41 (d, 1H, J=2.8 Hz, H-4); 5.32 5.13 (m, 1H, H-3); 4.10 3.83 (m, 3H,
H-5, H-6a, H-6b); 3.62 (t, 2H, 3J=6.3 Hz, CH2OH); 3.06 (d, 1H, 3J=
10.2 Hz, a-CH); 2.25 2.15, 2.03 1.95R (m, 1H, CHMe2); 1.33, 1.30, 1.29,
1.26, 1.12, 1.11, 1.10, 1.09 (m, 52H, 3îPiv tBu, tBu, 2îMe, 5îCH2);
1.03, 0.80R (d, 3J=6.3 Hz, Me); 0.96, 0.85R (d, 3J=6.7 Hz, Me) ppm; R
isomer: Yield: 4 mg, tR =20.1 min; 1H NMR (CDCl3, 400 MHz): d=
8.66R, 8.32 (s, 1H, CHO); 6.55 (s, 1H, NH); 5.96 (d, 1H, 3J=9.0 Hz, H-
1
colorless, amorphous solid; [a]2D5 =25.14 (c=1, CDCl3); H NMR (CDCl3,
400 MHz): d=8.44R, 8.15 (s, 1H, CHO); 7.36 7.34 (m, 5H, aryl); 6.08R,
3
5.31 (s, 1H, NH); 6.00, 4.76R (d, 1H, J=9.4 Hz, H-1); 5.52, 5.40R (t, 1H,
3J=9.8 Hz, H-2); 5.47, 5.39R (d, 1H, 3J=2.4 Hz, H-4); 5.24R, 4.84 (s, 1H,
a-CH); 5.19, 4.95R (dd, 1H, 3J=9.8, 3J=2.8 Hz, H-3); 4.14 3.94 (m, 3H,
H-5, H-6a, H-6b); 3.62, 3.61R (t, 2H, 3J=6.4 Hz, CH2OH); 1.87 (s, 1H,
OH); 1.57 1.18 (m, 10H, 5îCH2); 1.35, 1.30, 1.29, 1.28, 1.12, 1.11, 1.04,
1.00, 0.96 (several singlets, 42H, 3îPiv tBu, tBu, 2îMe) ppm; MS (ES+):
C44H70N2O12 (819.03): m/z: 838.6 [2M+Ca]+/2; 841.6 [M+Na]+; 857.6
[M+K]+; R isomer: tR =61.9 min; yield: 85 mg (48%); colorless, amor-
phous solid; [a]2D5 =ꢀ28.31 (c=1, CDCl3); elemental analysis: calcd (%):
C 64.52, H 8.61, N 3.42; found: C 63.04, H 8.89, N 3.24; 1H NMR
(CDCl3, 400 MHz): d=8.39R, 8.15 (s, 1H, CHO); 7.33 7.29 (m, 5H,
3
3
1); 5.53 (t, 1H, J=9.6 Hz, H-2); 5.42 (d, 1H, J=3.1 Hz, H-4); 5.17 (dd,
1H, 3J=9.8, 3J=2.8 Hz, H-3); 4.08 3.80 (m, 3H, H-5, H-6a, H-6b); 3.62
(t, 2H, 3J=6.3 Hz, CH2OH); 3.26 (d, 1H, J=10.1 Hz, a-CH); 2.46 2.35,
3
2.24 2.16R (m, 1H, CHMe2); 1.35, 1.30, 1.29, 1.11, 1.10, 1.09, 1.06 (m,
52H, 3îPiv tBu, tBu, 2îMe, 5îCH2); 1.01R, 0.97, 0.93R, 0.87 (d, 6H,
3J=6.6 Hz, 2îMe) ppm; MS (ES+): C41H72N2O12 (785.02): m/z: 807.7
[M+Na]+.
3
aryl); 5.87R, 5.30 (s, 1H, NH); 5.92, 5.10R (d, 1H, J=9.4 Hz, H-1); 5.55R,
(2R)-N-Formyl-N-[6-O-(8-hydroxy-2,2-dimethyloctanoyl)-2,3,4-tri-O-piv-
aloyl-b-d-galactopyranosyl]-norvaline-tert-butyl amide (13 g): Cleav-
age A: Yield: 4.4 mg (70%), colorless oil; Rf =0.33 (cyclohexane/ethyl
acetate (4:1)); LC-MS: tR =5.70 (minor); 6.05 (major) min; d.r. 9:91
(ELSD), purity: 95% (ELSD); MS (ES+): C41H72N2O12 (785.02): m/z:
807.7 [M+Na]+.
5.21 (t, 1H, 3J=9.8 Hz, H-2); 5.52R, 5.07 (s, 1H, a-CH); 5.43, 5.29R (d,
1H, 3J=2.3 Hz, H-4); 5.10 (dd, 1H, 3J=10.2, 3J=2.7 Hz, H-3); 4.20,
2
3
3
3.58R (dd, 1H, J=10.6, J=7.2 Hz, H-6a); 4.13, 3.58R (t, 1H, J=6.3 Hz,
H-5); 4.13, 3.58R (dd, 1H, 2J=10.9, J=5.3 Hz, H-6b); 3.59R, 3.53 (t, 1H,
3
3J=6.4 Hz, CH2OH); 2.10 (s, 1H, OH); 1.50 1.20 (m, 10H, 5îCH2);
1.34, 1.27, 1.20, 1.13, 1.11, 1.08, 1.07, 1.04 (several singlets, 42H, 3îPiv
tBu, tBu, 2îMe) ppm; 13C NMR (CDCl3, 100.6 MHz): d=177.4, 177.3,
(2R)-N-Formyl-N-[6-O-(8-hydroxy-2,2-dimethyloctanoyl)-2,3,4-tri-O-piv-
aloyl-b-d-galactopyranosyl]-leucine-tert-butyl amide (13h): Cleavage A:
Yield: 4.1 mg (64%), colorless oil; Rf =0.31 (cyclohexane/ethyl acetate
(4:1)); LC-MS: tR =6.77 (major); 7.13 (minor) min; d.r. 90:10 (ELSD),
purity: 96% (ELSD); MS (ES+): C42H74N2O12 (799.04): m/z: 821.7
[M+Na]+.
R
R
R
ꢀ
177.1 , 176.8 , 176.5 , 176.2, 176.1 (Piv C=O) ppm; 166.9 (CONHtBu);
164.7, 162.6R (CHO); 137.4, 135.5R (ipso-phenyl); 129.0, 128.8, 128.6,
128.4 (phenyl); 85.7R, 72.3 (C-3); 78.3 (C-1); 73.2 (C-5); 67.4 (C-4); 65.4
(C-2); 62.7 (CH2OH); 61.3 (C-6); 58.9 (a-C); 52.3, 51.6R (CMe3); 42.3
(CMe2); 40.4 (CH2); 39.1, 38.9R, 38.7, 38.6 (Piv CMe3); 32.7, 29.7 (2î
CH2); 28.8, 28.6R (tBu Me); 27.3, 27.2, 27.1 (Piv Me); 25.5, 25.1, 25.0,
24.8 (CH2, CMe2) ppm; MS (ES+): m/z: 838.6 [2M+Ca]+/2; 841.6
[M+Na]+; 857.6 [M+K]+.
General procedure for the formation of N-galactosyl aldimines (15) on
the solid phase: Galactosylamine resin 2a (75 mg, 0.03 mmol) was swol-
len in toluene (0.5 mL), the suspension was combined with the aldehyde
(5 equivalents, 0.15 mmol) in toluene (0.3 mL) and acetic acid (10 equiva-
lents, 18 mL, 0.30 mmol), and the mixture was shaken at room tempera-
ture for 6 h. After filtration and successive washing with dichloromethane
and methanol (6 cycles), the resin was dried in vacuo to constant weight
(approximately 2 h).
(2R)-N-Formyl-N-[6-O-(8-hydroxy-2,2-dimethyloctanoyl)-2,3,4-tri-O-piv-
aloyl-b-d-galactopyranosyl]-4-chlorophenylglycine-tert-butyl
amide
(13d): Cleavage A: Yield: 14.4 mg (84%), colorless oil; Rf =0.66 (petrole-
um ether/ethyl acetate (4:1)); LC-MS: tR =6.25 (minor); 7.53 (major)
min; d.r. 20:80 (ELSD), purity: 96% (ELSD). Isolation of the major dia-
stereomer by semi-preparative HPLC (Spherisorb C-18, MeCN (80%!
100%), 120 min): tR =20.1 min; 1H NMR (CDCl3, 400 MHz): d=8.35R,
8.19 (s, 1H, CHO); 7.37 7.21 (m, 4H, 4îaryl); 5.96R, 5.30 (s, 1H, NH);
5.93, 5.06R (d, 1H, 3J=9.4 Hz, H-1); 5.53R, 5.22 (t, 1H, 3J=9.7 Hz, H-2);
5.44, 5.35R (d, 1H, 3J=2.6 Hz, H-4); 5.31R, 5.02 (s, 1H, a-CH); 5.14,
5.12R (dd, 1H, 3J=10.1, 3J=2.6 Hz, H-3); 4.22 (dd, 1H, 2J=11.1, 3J=
7.4 Hz, H-6a); 4.13 (dd, 1H, 3J=7.0, 3J=5.6 Hz, H-5); 3.94 (dd, 1H, 2J=
11.1, 3J=5.3 Hz, H-6b); 3.60, 3.57R (t, 1H, 3J=6.4 Hz, CH2OH); 1.49
1.43, 1.36, 1.29, 1.24, 1.14, 1.12, 1.10 (m, 52H, 3îPiv tBu, tBu, 2îMe, 5î
CH2) ppm; MS (ES+): C44H69ClN2O12 (853.48): m/z: 875.6 [M(35Cl)+Na]+;
877.6 [M(37Cl)+Na]+.
General procedure for the tandem Mannich Michael reaction on the
solid phase–Synthesis of dehydropiperidinones 18: Galactosyl aldimine
resin 15 (75 mg, 0.03 mmol) was swollen in dry THF (1 mL), then zinc
chloride (1m in THF; 0.15 mL, 0.15 mmol) and diene 16 (59 mL,
0.30 mmol) were added at room temperature. The suspension was shaken
for 48 h, treated with 1n HCl (0.1 mL), shaken for a further 10 minutes,
and filtered, then the resin was washed with dichloromethane, THF, and
methanol (6 cycles). Subsequent cleavage from the support by using
either cleavage method A or B (see above) delivered dehydropiperidi-
nones 18.
(2S)-N-[6-O-(8-Hydroxy-2,2-dimethyloctanoyl)-2,3,4-tri-O-pivaloyl-b-d-
galacto-pyranosyl]-2-phenyl-5,6-didehydro-piperidin-4-one (18a): Cleav-
age A: Yield: 19.1 mg (81%); colorless oil; Rf =0.41 (petroleum ether/
ethyl acetate (1:1)); LC-MS: tR =3.85 (minor); 4.20 (major) min; d.r. 5:95
(ELSD), purity: 98% (ELSD); 1H NMR (CDCl3, 200 MHz): d=7.37
7.28 (m, 6H, 5îaryl, NCH=CH); 5.56 (t, 1H, 3J=9.8 Hz, H-2); 5.29 (d,
1H, 3J=2.9 Hz, H-4); 5.25 (d, 1H, 3J=8.4 Hz, NCH=CH); 4.93 (dd, 1H,
3J=9.8, 3J=2.9 Hz, H-3); 4.80 (dd, 1H, 3J=9.0, 3J=7.1 Hz, NCHPh);
4.27 (d, 1H, 3J=9.3 Hz, H-1); 3.97 (dd, 1H, 3J=6.8, 2J=10.7 Hz, H-6a);
3.81 3.56 (m, 4H, H-5, H-6b, CH2OH); 2.83 2.70 (m, 2H, CH2C=O);
1.51 1.20 (m, 10H, 5îCH2); 1.25, 1.16, 1.08 (3 s, 27H, Piv tBu); 1.12 (s,
6H, 2îMe) ppm; MS (ES+): C42H63NO11 (757.95): m/z: 758.6 [M+H]+;
780.6 [M+Na]+.
(2R)-N-Formyl-N-[6-O-(8-hydroxy-2,2-dimethyloctanoyl)-2,3,4-tri-O-piv-
aloyl-b-d-galactopyranosyl]-4-methoxyphenylglycine-tert-butyl
amide
(13e): Cleavage A: Yield: 17 mg (67%), colorless oil; Rf =0.53 (cyclohex-
ane/ethyl acetate (1:1)); [a]D25 =ꢀ26.91 (c=0.5, CDCl3); LC-MS: tR =4.78
(minor); 6.25 (major) min; d.r. 6:94 (ELSD), purity 98% (ELSD);
1H NMR (CDCl3, 400 MHz): d=8.39R, 8.18 (s, 1H, CHO); 7.34R, 7.27 (d,
3
3
2H, J=8.8 Hz, 2îaryl); 6.84 (d, 2H, J=8.6 Hz, 2îaryl); 5.93, 5.01R (d,
1H, 3J=9.4 Hz, H-1); 5.72R, 5.21 (s, 1H, NH); 5.56R, 5.22 (t, 1H, 3J=
9.6 Hz, H-2); 5.45, 5.31R (d, 1H, 3J=2.4 Hz, H-4); 5.42R, 5.03 (s, 1H, a-
3
3
2
3
CH); 5.11 (dd, 1H, J=9.8, J=2.7 Hz, H-3); 4.25 (dd, 1H, J=11.0, J=
7.4 Hz, H-6a); 4.14 (t, 1H, 3J=6.6 Hz, H-5); 3.98 (dd, 1H, 2J=11.3, 3J=
5.7 Hz, H-6b); 3.78 (s, 3H, OMe); 3.61R, 3.57 (t, 1H, 3J=6.6 Hz,
CH2OH); 1.53 1.21, 1.35, 1.29, 1.28R, 1.23R, 1.15R, 1.13, 1.09, 1.06R (m,
52H, 3îPiv tBu, tBu, 2îMe, 5îCH2) ppm; MS (ES+): C45H72N2O13
(849.06): m/z: 871.6 [M+Na]+.
(2S)-N-[6-O-(8-Hydroxy-2,2-dimethyloctanoyl)-2,3,4-tri-O-pivaloyl-b-d-
galacto-pyranosyl]-2-(4-fluorophenyl)-5,6-didehydro-piperidin-4-one
(18b): Cleavage A: Yield: 18.2 mg (77%); colorless oil; Rf =0.37 (petro-
4144
¹ 2004 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Chem. Eur. J. 2004, 10, 4136 4149